Compare FEAM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | BLRX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 12.0M |
| IPO Year | 2022 | 2010 |
| Metric | FEAM | BLRX |
|---|---|---|
| Price | $2.41 | $2.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.38 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 516.0K | 19.4K |
| Earning Date | 05-20-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $2.15 |
| 52 Week High | $7.50 | $4.56 |
| Indicator | FEAM | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 75.23 | 40.14 |
| Support Level | $1.48 | $2.18 |
| Resistance Level | $2.59 | $2.51 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 97.58 | 2.12 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.